What You Need to Know About Prescribing Paxlovid

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients

The Body of Evidence for Paxlovid Therapy Dr Eric Topol, Medscape's editor-in-chief, writes that there is compelling evidence to use Paxlovid in COVID patients ages 60 and up. "We should be thinking of why we should be using Paxlovid rather than the reason not to treat," Dr Topol writes.
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19 Nirmatrelvir-ritonavir (NMVr) may have significant interactions with cardiovascular drugs. This paper reviews common ones and the importance of medication reconciliation before initiation of NMVr.
Journal of the American College of Cardiology
Paxlovid Detailed Information Paxlovid may be prescribed by physicians, advanced practice registered nurses, physician assistants licensed or authorized by state law, and state-licensed pharmacists.
Drug Interaction Checker Nirmatrelvir/ritonavir has a number of potential drug interactions that prescribers need to be aware of to help make a treatment decision.
COVID-19 Treatment: Investigational Drugs and Other Therapies The antiviral drug nirmatrelvir/ritonavir was issued an EUA for treatment of mild-to-moderate COVID-19 in adults and pediatric outpatients (age 12 years or older) who are at high risk for severe illness.

No Results